Aardvark Therapeutics (AARD) Cash & Equivalents (2024 - 2026)

Aardvark Therapeutics (AARD) has 3 years of Cash & Equivalents data on file, last reported at $91.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 39.72% year-over-year to $91.2 million; the trailing twelve-month figure through Mar 2026 stood at $91.2 million (down 39.72% YoY), and the FY2025 full-year result was $47.1 million, down 23.67% from the prior year.
• Cash & Equivalents advanced to $91.2 million in Q1 2026, from $47.1 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $151.3 million in Q1 2025 to a low of $47.1 million in Q4 2025.
• A 3-year average of $103.2 million and a median of $108.8 million in 2025 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents dropped 23.67% in 2025 and sank 39.72% in 2026, its largest moves.
• Tracing AARD's Cash & Equivalents over 3 years: stood at $61.6 million in 2024, then retreated by 23.67% to $47.1 million in 2025, then surged by 93.83% to $91.2 million in 2026.
• Business Quant data shows AARD's Cash & Equivalents at $91.2 million in Q1 2026, $47.1 million in Q4 2025, and $126.4 million in Q3 2025.